Related Experiment Videos
[Clinical applications of G-CSF]
1Dept. of Hematology-Oncology, University of Tokyo.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1990
Summary
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) effectively supports bone marrow transplantation and reduces infection risks in cancer patients. Clinical studies confirm rhG-CSF
Area of Science:
- Biochemistry and Molecular Biology
- Hematology
- Immunology
Context:
- Granulocyte colony-stimulating factor (G-CSF) is a critical glycoprotein hormone regulating neutrophil production and function.
- Malignant neoplastic disorders compromise immune function and hematopoietic processes.
- Recombinant human G-CSF (rhG-CSF) offers potential therapeutic benefits in oncology and hematology.
Purpose:
- To evaluate the safety and efficacy of rhG-CSF in patients with malignant neoplastic disorders.
- To explore rhG-CSF's role in mitigating infectious complications.
- To assess rhG-CSF's utility in bone marrow transplantation and direct anti-cancer effects.
Summary:
- rhG-CSF, a recombinant form of G-CSF, demonstrates significant biological actions including hematopoietic stem cell release, enhanced neutrophil production, prolonged neutrophil survival, and stimulation of myeloid leukemia cell growth.
- Clinical studies utilizing rhG-CSF derived from Chinese hamster ovary cells have been conducted.
- Results indicate that rhG-CSF can be safely and efficiently administered for therapeutic purposes in patients with cancer.
Impact:
- rhG-CSF can reduce the risk of infectious complications in cancer patients.
- It may enhance the effectiveness of treatments aimed at killing malignant cells.
- rhG-CSF shows promise in promoting successful bone marrow transplantation.